Disease relevance of Span 85

• An experimental oil adjuvant vaccine was developed against haemorrhagic septicaemia, a disease of cattle and buffalo caused by Pasteurella multocida serotype B and E. Mineral oil, Mercol 52, was used as adjuvant together with Span 85 and Tween 85 as emulsifiers [1].

High impact information on Span 85

• Characterization of Lipase in Reversed Micelles Formulated with Cibacron Blue F-3GA Modified Span 85 [2].
• The nonionic surfactant of sorbitan trioleate (Span 85) was modified with Cibacron Blue F-3GA (CB) as an affinity surfactant (CB-Span 85) to form affinity-based reversed micelles in n-hexane [3].
• Bacitracin and Span 85, which are potent pulmonary absorption enhancers of insulin formulated in solutions, showed no deteriorative effect on the stability of dry insulin powder [4].
• The combination of NaCl/NaHCO3 (pH 10) and Span 85 did not detach cells possibly due to reduced hydrophobicity of the Span at this pH [5].
• There is no optimal surfactant mixture for stabilization of any lipid, e.g. SLN consisting of the lipid Cutina CP showed GIT stability in combination with the stabilizer sugar ester S1670, whereas the stabilization with the surfactant mixture Tween 80/Span 85 was not effective [6].

Biological context of Span 85

• The insulin dry powder with 0.21 mg/dose of Span 85 showed a bioavailability less than that for the insulin solution with 0.1 mg/dose of Span 85 [7].

Anatomical context of Span 85

• The surfactants investigated were Span 85, Span 80, Span 40, egg yolk lecithin, and Tween 80 [8].

Associations of Span 85 with other chemical compounds

• The nonionic surfactant of sorbitan trioleate (Span 85) was modified with Cibacron Blue F-3GA (CB) as an affinity surfactant (CB-Span 85) to form affinity-based reverse micelles in n-hexane [9].

Analytical, diagnostic and therapeutic context of Span 85

• At high Span 85 concentration (1.5% w/v), the external surface of the microspheres collapsed, but the internal structure remained dense [10].

References